Apogee Pharmaceuticals, Inc. (Apogee) is redefining women’s health through precision, mechanism‑driven therapeutics. We unite scientific rigor with entrepreneurial agility to target the debilitating symptoms that affect women worldwide, due to chronic pain, infertility, inflammation, and other life‑altering manifestations of complex diseases . With a focus on high‑unmet‑need conditions such as endometriosis and adenomyosis, Apogee is developing and acquiring next‑generation therapies and diagnostics. In parallel, we are advancing existing programs that modulate the endocannabinoid system (ECS) to unlock its therapeutic potential in women’s health. Headquartered in Greater Vancouver, British Columbia, Apogee operates a 5,000‑square‑foot research facility and wet laboratory staffed by a world‑class team committed to translating breakthrough science into life‑changing treatments.

Apogee has a bold vision to transform immune‑based therapeutics in women’s health by pairing scientific rigor with operational excellence. Guided by leaders from global pharma and biotech, and backed by a healthcare-focused investment firm, we apply AI‑ and machine‑learning‑enabled discovery to accelerate precision development. With Apogee’s existing strong financial support and disciplined execution, Apogee is positioned to move decisively, scale rapidly, and deliver transformative therapies and diagnostics with speed, precision, and purpose.